Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
2.250
-0.060 (-2.60%)
Aug 15, 2025, 10:24 AM - Market open
Purple Biotech Employees
Purple Biotech had 9 employees as of December 31, 2024. The number of employees decreased by 11 or -55.00% compared to the previous year.
Employees
9
Change (1Y)
-11
Growth (1Y)
-55.00%
Revenue / Employee
n/a
Profits / Employee
-$290,111
Market Cap
6.63M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9 | -11 | -55.00% |
Dec 31, 2023 | 20 | 0 | - |
Dec 31, 2022 | 20 | 1 | 5.26% |
Dec 31, 2021 | 19 | 6 | 46.15% |
Dec 31, 2020 | 13 | 4 | 44.44% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PPBT News
- 9 days ago - Purple Biotech Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 23 days ago - Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 - GlobeNewsWire
- 7 weeks ago - Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress - GlobeNewsWire
- 3 months ago - Purple Biotech Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Purple Biotech Appoints Shai Lankry as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers - GlobeNewsWire
- 5 months ago - Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 6 months ago - Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewsWire